dihydroxyphenylalanine

Summary

Summary: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.

Top Publications

  1. ncbi Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 92:4706-11. 2007
  2. ncbi Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET
    H Christian Rischke
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 53:1352-8. 2012
  3. ncbi Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer
    Michael Soussan
    Department of Nuclear Medicine, Tenon Hospital, AP HP, University Paris 6, Paris, France
    Nucl Med Commun 33:775-9. 2012
  4. ncbi Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study
    Stephen McGowan
    Cyclotron Unit, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, Imperial College, London, England
    Arch Gen Psychiatry 61:134-42. 2004
  5. ncbi Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA
    Maria Joao Ribeiro
    Service Hospitalier Frederic Joliot, Departement de Recherche Medicale, Direction des Sciences du Vivant, Commissariat a l Energie Atomique, Orsay, France
    J Nucl Med 46:560-6. 2005
  6. ncbi Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
    Giorgio Treglia
    Institute of Nuclear Medicine, Policlinico A Gemelli, Catholic University of the Sacred Heart, Rome, Italy
    Eur J Nucl Med Mol Imaging 39:569-80. 2012
  7. ncbi The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy
    Augusto Zani
    Department of Paediatric Surgery, Institute of Child Health and Great Ormond Street Hospital for Children, Great Ormond Street, London, United Kingdom
    J Pediatr Surg 46:204-8. 2011
  8. ncbi The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Mohsen Beheshti
    Department of Nuclear Medicine and Endocrinology, PET CT Center LINZ, St Vincent s Hospital, Seilerstaette 4, 4020, Linz, Austria
    Eur Radiol 19:1425-34. 2009
  9. ncbi Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
    Valentina Ambrosini
    Unità Operativa di Medicina Nucleare, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Padiglione 30, Via Massarenti 9, 40138, Bologna, Italy
    Eur J Nucl Med Mol Imaging 35:1431-8. 2008
  10. ncbi The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma
    Henri J L M Timmers
    Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 1109, USA
    J Nucl Med 48:1599-606. 2007

Detail Information

Publications256 found, 100 shown here

  1. ncbi Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 92:4706-11. 2007
    ..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs...
  2. ncbi Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET
    H Christian Rischke
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 53:1352-8. 2012
    ..Furthermore, we assessed whether the genotypes of pheochromocytomas and paragangliomas correlate with the uptake of (18)F-DOPA...
  3. ncbi Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer
    Michael Soussan
    Department of Nuclear Medicine, Tenon Hospital, AP HP, University Paris 6, Paris, France
    Nucl Med Commun 33:775-9. 2012
    ..The only false-positive case, a reactive lymph node, was visible only on the delayed acquisition. Early acquisition appeared to be more appropriate in the detection of MTC lesions compared with acquisition at 60 min or later...
  4. ncbi Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study
    Stephen McGowan
    Cyclotron Unit, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, Imperial College, London, England
    Arch Gen Psychiatry 61:134-42. 2004
    ..The dopamine overactivity hypothesis of schizophrenia remains one of the most influential theories of the pathophysiology of the illness. Radiotracer brain imaging studies are now directly testing aspects of the overactivity hypothesis...
  5. ncbi Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA
    Maria Joao Ribeiro
    Service Hospitalier Frederic Joliot, Departement de Recherche Medicale, Direction des Sciences du Vivant, Commissariat a l Energie Atomique, Orsay, France
    J Nucl Med 46:560-6. 2005
    ..Therefore, the aim of this study was (a) to evaluate the use of PET with 18F-fluoro-L-dihydroxyphenylalanine (18F-fluoro-L-DOPA) and (b) to distinguish between focal and diffuse HI.
  6. ncbi Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
    Giorgio Treglia
    Institute of Nuclear Medicine, Policlinico A Gemelli, Catholic University of the Sacred Heart, Rome, Italy
    Eur J Nucl Med Mol Imaging 39:569-80. 2012
    ..To retrospectively evaluate and compare (18)F-FDG, (18)F-DOPA and (68)Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels...
  7. ncbi The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy
    Augusto Zani
    Department of Paediatric Surgery, Institute of Child Health and Great Ormond Street Hospital for Children, Great Ormond Street, London, United Kingdom
    J Pediatr Surg 46:204-8. 2011
    In congenital hyperinsulinism (CHI) of infancy, the use of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine-positron emission tomography-computed tomography ((18)F-DOPA-PET-CT) scan has recently been reported...
  8. ncbi The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
    Mohsen Beheshti
    Department of Nuclear Medicine and Endocrinology, PET CT Center LINZ, St Vincent s Hospital, Seilerstaette 4, 4020, Linz, Austria
    Eur Radiol 19:1425-34. 2009
    ....
  9. ncbi Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
    Valentina Ambrosini
    Unità Operativa di Medicina Nucleare, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Padiglione 30, Via Massarenti 9, 40138, Bologna, Italy
    Eur J Nucl Med Mol Imaging 35:1431-8. 2008
    ..At present, there are no comparative studies investigating their role in NET...
  10. ncbi The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma
    Henri J L M Timmers
    Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 1109, USA
    J Nucl Med 48:1599-606. 2007
    6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful tool for the detection of certain neuroendocrine tumors, especially with the preadministration of carbidopa, an inhibitor of DOPA decarboxylase...
  11. ncbi The surgical management of congenital hyperinsulinemic hypoglycemia in infancy
    C Nihoul Fékété
    Department of Pediatric Surgery, Hopital des Enfants Malades, Paris, France
    J Pediatr Surg 39:267-9. 2004
    ..It is therefore mandatory to distinguish the 2 forms of CHI, and the surgeon has to fullfill his role in the multidisciplinary team that deals with CHI...
  12. ncbi Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid
    Klaas P Koopmans
    Department of Nuclear Medicine and PET Center, University Medical Center Groningen, Groningen, The Netherlands
    J Nucl Med 46:1240-3. 2005
    ..Octreotide can be used for treatment and should be available. Tracer injection should be slow...
  13. ncbi Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion
    Pascale de Lonlay
    Departement de Pediatrie, Hopital Necker Enfants Malades, Universite Paris Descartes, Faculte de Medecine, 149 rue de Sevres, 75743 Paris Cedex 15, France
    J Clin Endocrinol Metab 91:933-40. 2006
    ..Preoperative differential diagnosis was based on pancreatic venous sampling, a technically demanding technique...
  14. ncbi Visualization of the gall bladder on F-18 FDOPA PET imaging: a potential pitfall
    Kottekkattu K Balan
    Department of Nuclear Medicine, Addenbrooke s Hospital, Cambridge, UK
    Clin Nucl Med 30:23-4. 2005
  15. ncbi Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography
    Klaas P Koopmans
    Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    J Clin Oncol 26:1489-95. 2008
    ..To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers...
  16. ncbi 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation
    Klaas P Koopmans
    Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
    J Nucl Med 49:524-31. 2008
    ..Therefore, the value of 18F-dihydroxyphenylalanine PET (18F-DOPA PET), 18F-FDG PET, (99m)Tc-V-di-mercaptosulfuricacid (DMSA-V) scintigraphy, and MRI or CT ..
  17. pmc The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function
    Alice Egerton
    Psychiatric Imaging, Medical Research Council Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, UK
    Neuroimage 50:524-31. 2010
    ..This information can be used to optimize the experimental design of future studies investigating changes in brain dopaminergic function with 18F-DOPA...
  18. ncbi Utility of MLPA in deletion analysis of GCH1 in dopa-responsive dystonia
    Daniela Steinberger
    Institut fur Humangenetik, Justus Liebig Universitat, Giessen, Germany
    Neurogenetics 8:51-5. 2007
    ..The findings were confirmed by quantitative real-time PCR. Our investigations demonstrate the utility of MLPA for routine deletion analysis of GCH1 in DRD patients with no sequence changes in this gene...
  19. ncbi High frequency of multiexonic deletion of the GCH1 gene in a Taiwanese cohort of dopa-response dystonia
    Yah Huei Wu-Chou
    Human Molecular Genetics Laboratory, Department of Medical Research, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan
    Am J Med Genet B Neuropsychiatr Genet 153:903-8. 2010
    ..By dosage analysis, we were able to detect a mutation in all patients. Our study demonstrates that dosage analysis is necessary for molecular diagnostics in DRD patients of Han Chinese ethnicity...
  20. ncbi Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism
    Carmen Capito
    Departments of Pediatric Surgery, Radiology, Pathology, and Pediatrics, Necker Enfants Malades Hospital, AP HP, 75015 Paris, France
    Radiology 253:216-22. 2009
    ....
  21. ncbi Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis
    Giorgio Treglia
    Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8, 00168 Rome, Italy
    Acad Radiol 19:1290-9. 2012
    ..of this study was to perform a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) or PET/computed tomography (CT) in detecting recurrent medullary ..
  22. ncbi Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis
    Giorgio Treglia
    Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy
    Eur J Nucl Med Mol Imaging 39:1144-53. 2012
    ..The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG).
  23. ncbi 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours
    Sotirios Chondrogiannis
    Department of Nuclear Medicine, PET CT Center, Santa Maria della Misericordia Hospital Rovigo, Rovigo, Italy
    Nucl Med Commun 33:179-84. 2012
    L-6-fluoro 3,4-dihydroxyphenylalanine (18F-DOPA), an amino acid-based radiopharmaceutical, is increasingly being used in the detection and management of neuroendocrine tumours...
  24. ncbi Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients
    D Putzer
    Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
    Q J Nucl Med Mol Imaging 54:68-75. 2010
    68)Ga-DOTA-Tyr3-octreotide positron emission tomography ((68)Ga-DOTA-TOC PET) and (18)F-fluoro-L-dihydroxyphenylalanine PET ((18)F-DOPA PET) are emerging modalities for imaging of neuroendocrine tumors...
  25. pmc Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors
    Marina S Zemskova
    Building 10, CRC, 1 East, Room 1 3140, 10 Center Drive, MSC 1109, Bethesda, Maryland 20892 1109, USA
    J Clin Endocrinol Metab 95:1207-19. 2010
    ..Because ectopic ACTH-secreting (EAS) tumors are often occult, improved imaging is needed...
  26. ncbi Dopa-responsive dystonia
    Masaya Segawa
    Segawa Neurological Clinic for Children, Tokyo, Japan
    Handb Clin Neurol 100:539-57. 2011
    ..In recessive disorders, hypofunction of serotonin and noradrenaline induces hypofunction of the dopamine in the perikaryon and shows cortical dysfunction...
  27. ncbi Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours
    M Schiesser
    Department of Surgery, University Hospital Zurich, Zurich, Switzerland
    Br J Surg 97:691-7. 2010
    ..This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography-computed tomography (18F-DOPA-PET/CT) in the management of NET...
  28. ncbi Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors
    Francoise Montravers
    Department of Nuclear Medicine, Tenon Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    J Clin Endocrinol Metab 94:1295-301. 2009
    ..This study was conducted to evaluate the impact of FDOPA-PET on the management of patients referred for carcinoid or noncarcinoid digestive tumors and the clinical relevance of the treatment decisions based on this examination...
  29. ncbi 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data
    Jean Noel Talbot
    Médecine nucléaire et Centre TEP AP HP, Hopital Tenon, Paris, France
    Mol Imaging Biol 7:257-61. 2005
    ..As 6-[F-18]fluoro-L-DOPA (FDOPA) is taken up by other neuroendocrine tumors, we speculated that FDOPA-PET could image MCC...
  30. ncbi Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging
    M C Marzola
    Department of Nuclear Medicine, Medical Physics, Radiology, Santa Maria della Misericordia Hospital, Viale Tre Martiri 140, 45100, Rovigo, Italy
    Eur J Surg Oncol 36:414-21. 2010
    ..To evaluate the role of a multi-imaging PET with (18)F-DOPA and (18)F-FDG in comparison with conventional imaging (CI) in recurrent medullary thyroid carcinoma (MTC)...
  31. ncbi Pheochromocytomas: detection with 18F DOPA whole body PET--initial results
    Stefan Hoegerle
    Divisions of Nuclear Medicine, Department of Radiology, Albert Ludwigs University, Freiburg, Germany
    Radiology 222:507-12. 2002
    To evaluate fluorine 18 ((18)F) dihydroxyphenylalanine (DOPA) whole-body positron emission tomography (PET) as a biochemical imaging approach for detection of pheochromocytomas.
  32. ncbi Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results
    Thierry Jacob
    Department of Nuclear Medicine, Tenon Hospital and APHP PET Center, 75020 Paris, France
    Eur J Nucl Med Mol Imaging 30:1266-9. 2003
    Small cell lung carcinomas (SCLC) express neuroendocrine markers, and dihydroxyphenylalanine (DOPA) is known to accumulate in neuroendocrine tumours...
  33. ncbi Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors
    S Hoegerle
    Department of Radiology, Division of Nuclear Medicine, Albert-Ludwigs University, Hugstetterstrasse 55, 79106 Freiburg, Germany
    Radiology 220:373-80. 2001
    ..CONCLUSION: 18F dopa PET is a promising procedure and useful supplement to morphologic methods in diagnostic imaging of gastrointestinal carcinoid tumors...
  34. ncbi The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children
    Maria Joao Ribeiro
    Biomedical Imaging Institute, Life Sciences Division, Commissariat a l Energie Atomique, Frédéric Joliot Hospital, 4 Place du General Leclerc, Orsay, France
    Eur J Nucl Med Mol Imaging 34:2120-8. 2007
    ..Here, we report the diagnostic value of PET with [(18)F]fluoro-L-DOPA in distinguishing focal from diffuse HI...
  35. ncbi 18F-FDOPA kinetics in brain tumors
    Christiaan Schiepers
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Nucl Med 48:1651-61. 2007
    ..Evaluation of tumor recurrence in neurooncology is another application. Here, the kinetics of (18)F-FDOPA in brain tumors were investigated...
  36. ncbi 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications
    Pieter L Jager
    Department of Nuclear Medicine, Hamilton Health Sciences McMaster University, Hamilton, Ontario, Canada
    J Nucl Med 49:573-86. 2008
    ..In the remaining conditions, the initial experience with 18F-DOPA PET indicates that it seems to be less valuable, but further study is required...
  37. pmc Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma
    Henri J L M Timmers
    Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 94:4757-67. 2009
    ..positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including (18)F-3,4-dihydroxyphenylalanine (DOPA), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), and (18)F-fluorodopamine ((18)F-FDA).
  38. ncbi Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients
    Saila Kauhanen
    Turku PET Centre, Department of Surgery, Turku University Hospital, P O Box 52, FIN 20521 Turku, Finland
    J Clin Endocrinol Metab 92:1237-44. 2007
    Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) is a promising method in localizing neuroendocrine tumors...
  39. ncbi Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET
    Alexander Becherer
    Department of Nuclear Medicine, University of Vienna, Medical School, Vienna, Austria
    J Nucl Med 45:1161-7. 2004
    ..Based on the ability of NETs to store biogenic amines, this study evaluated whether 6-(18)F-fluoro-L-DOPA ((18)F-FDOPA) is a suitable PET tracer for NETs...
  40. ncbi Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany
    Eur J Nucl Med Mol Imaging 37:484-93. 2010
    ..The aim of this study was to investigate whether combined (18)F-DOPA PET/CT more accurately detects and localizes PHEO lesions than does each modality alone...
  41. ncbi The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas
    D Taieb
    Service Central de Biophysique et de Medecine Nucleaire, Centre Hospitalo Universitaire de la Timone, Marseille Cedex 5, France
    Clin Endocrinol (Oxf) 69:580-6. 2008
    ..18)F-DOPA has emerged as a promising tool in the localization of chromaffin-tissue-derived tumours. Interestingly, phaeochromocytomas (PHEO) are also FDG avid...
  42. ncbi 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
    S Hoegerle
    Department of Radiology, Albert-Ludwigs University Freiburg, Germany
    Eur J Nucl Med 28:64-71. 2001
    ..In the present study, the new procedure of fluorine-18 dihydroxyphenylalanine positron emission tomography (18F-DOPA PET) was compared with the established functional and morphological ..
  43. ncbi 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transpo
    C Fottner
    I Medical Clinic, Department of Endocrinology and Metabolism, University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
    J Clin Endocrinol Metab 95:2800-10. 2010
    ..Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy...
  44. ncbi 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine exces
    Helle Brit Fiebrich
    Department of Medical Oncology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands
    J Clin Endocrinol Metab 94:3922-30. 2009
    ..Catecholamine excess is rare, but symptoms may be life threatening...
  45. ncbi 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas
    Farzin Imani
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 50:513-9. 2009
    ..Herein, we investigated the accuracy of PET using 3,4-dihydroxy-6-(18)F-fluoro-phenylalanine ((18)F-FDOPA), an amino acid transporter substrate, as an independent marker for detection of benign and malignant pheochromocytomas...
  46. ncbi Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism
    Winfried Barthlen
    Clinic for Pediatric Surgery, Institute for Pathology, Charite University Medicine Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, Mittelallee 8, D 13353 Berlin, Germany
    J Clin Endocrinol Metab 93:869-75. 2008
    ..In congenital hyperinsulinism (CHI), the identification and precise localization of a focal lesion is essential for successful surgery...
  47. ncbi Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma
    Vittoria Rufini
    Institute of Nuclear Medicine, Catholic University of Sacred Heart, Rome, Italy
    Nucl Med Commun 32:575-82. 2011
    ..single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (18F-DOPA PET-CT) in the re-staging of patients with known or suspected ..
  48. ncbi Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity
    Ruediger Hilker
    Department of Neurology, University of Cologne, Cologne, Germany
    Arch Neurol 62:378-82. 2005
    ..The investigation of disease progression provides important information on the dynamics of cell death in Parkinson disease (PD)...
  49. ncbi Feasibility of carbidopa premedication in pediatric patients: a pilot study
    Egesta Lopci
    Department of Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy
    Cancer Biother Radiopharm 27:729-33. 2012
    ..To verify the potential role and feasibility of carbidopa premedication in pediatric patients undergoing ¹⁸F-DOPA (Fluorine-18 fluorodihydroxyphenylalanine) PET scanning...
  50. ncbi [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism
    K Mohnike
    Department of Pediatrics, Otto von Guericke University Magdeburg, Magdeburg, Germany
    Horm Res 70:65-72. 2008
    ..Fluorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA-PET) has been introduced for differentiation between focal and ..
  51. ncbi Quantitation of protein-bound 3-nitrotyrosine and 3,4-dihydroxyphenylalanine by high-performance liquid chromatography with electrochemical array detection
    K Hensley
    Oklahoma Medical Research Foundation, 825 N E 13th Street, Oklahoma City, Oklahoma, 73104, USA
    Anal Biochem 251:187-95. 1997
    ..array (HPLC-EC) detection to allow ultrasensitive determination of protein-bound 3-nitrotyrosine and 3, 4-dihydroxyphenylalanine (3-hydroxytyrosine) as specific in situ biomarkers of protein exposure to reactive nitrating and oxidizing ..
  52. pmc High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats
    Emilie Lacombe
    Institut National de la Sante et de la Recherche Medicale, Unite 836, Grenoble Institut des Neurosciences, Equipe Dynamique des Réseaux Neuronaux du Mouvement, Grenoble, France
    Eur J Neurosci 26:1670-80. 2007
    ..It results in clinical improvement in patients with PD, further reducing the l-3,4-dihydroxyphenylalanine (L-DOPA) requirement and thus L-DOPA-induced dyskinesia...
  53. ncbi Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma
    B Beuthien-Baumann
    Department of Nuclear Medicine, Universitatsklinikum Carl Gustav Carus, Technische Universität Dresden and PET Center Dresden Rossendorf, Fetscherstrasse 74, 01307 Dresden, Germany
    Eur J Nucl Med Mol Imaging 34:1604-9. 2007
    ..For positron emission tomography (PET) with (18)F-fluorodeoxyglucose ((18)F-FDG) and (18)F-dihydroxyphenylalanine ((18)F-DOPA), sensitivities of 78% and 63% have been reported, but in a considerable percentage of MTC ..
  54. ncbi Translational incorporation of L-3,4-dihydroxyphenylalanine into proteins
    Kiyoshi Ozawa
    Research School of Chemistry, Australian National University, Canberra, Australia
    FEBS J 272:3162-71. 2005
    ..coli cell-free transcription/translation system was used to explore the high-level incorporation of L-3,4-dihydroxyphenylalanine (DOPA) into proteins by replacing tyrosine with DOPA in the reaction mixtures...
  55. ncbi Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia
    L Tessonnier
    Service Central de Biophysique et de Medecine Nucleaire, Centre Hospitalo Universitaire Timone, 13385 Marseille Cedex 5, France
    J Clin Endocrinol Metab 95:303-7. 2010
    Fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-FDOPA PET) imaging is increasingly used in the workup of neuroendocrine tumors...
  56. ncbi Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Germany
    Thyroid 20:527-33. 2010
    ..The aim of this study was therefore to test the hypothesis that combined (18)F-DOPA PET/CT more accurately detects MTC lesions than each modality does alone...
  57. pmc Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
    Helle Brit Fiebrich
    Department of Medical Oncology, University Medical Centre Groningen, P O Box 30 001, 9700 RB, Groningen, The Netherlands
    Eur J Nucl Med Mol Imaging 38:1854-61. 2011
    Positron emission tomography (PET) using 6-[18F]fluoro-L-dihydroxyphenylalanine (18F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions...
  58. ncbi Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer
    Saila Kauhanen
    Turku PET Centre, Turku University Hospital, Turku, Finland
    J Nucl Med 52:1855-63. 2011
    ..Our aim was to compare fluorine-labeled dihydroxyphenylalanine ((18)F-DOPA) and (18)F-FDG PET/CT with multidetector CT (MDCT) and MRI in recurrent or persistent MTC.
  59. ncbi Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma
    Hans H G Verbeek
    Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands
    J Nucl Med 53:1863-71. 2012
    ..We compared (18)F-FDG PET and (18)F-dihydroxyphenylanaline ((18)F-DOPA) PET with biochemical parameters and survival to assess whether these imaging modalities could be of value in detecting progressive disease...
  60. ncbi PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study
    A Lange-Nolde
    Division of Nuclear Medicine, University Clinic Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
    Nuklearmedizin 45:193-6. 2006
    ....
  61. pmc Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome
    Allison B Weisbrod
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Clinical Research Center, Building 10 CRC, Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E613-7. 2012
    ..There are limited data on the clinical utility of using ¹⁸F-FDOPA PET for identifying neuroendocrine tumors in a high-risk population such as VHL...
  62. ncbi A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing's syndrome
    S Dubois
    Departement d Endocrinologie, Centre Hospitalier Universitaire, 4 rue Larrey, 49933 Angers cedex 09, France
    J Clin Endocrinol Metab 92:4512-3. 2007
  63. ncbi Diagnostic accuracy of [¹⁸F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan
    Michiya Masue
    Department of Pediatrics, Kizawa Memorial Hospital, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Gifu, Japan
    Clin Endocrinol (Oxf) 75:342-6. 2011
    We aimed to elucidate the accuracy and limitations of [(18)F]-fluoro-L-dihydroxyphenylalanine ([(18) F]DOPA) positron emission tomography (PET) for Japanese patients with congenital hyperinsulinism...
  64. pmc Identification of residue-to-residue contact between a peptide ligand and its G protein-coupled receptor using periodate-mediated dihydroxyphenylalanine cross-linking and mass spectrometry
    George K E Umanah
    Department of Microbiology, University of Tennessee, Knoxville, Tennessee 37996, USA
    J Biol Chem 285:39425-36. 2010
    ..The Trp(1) residue of α-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated chemical cross-linking, and biotin was conjugated to Lys(7) for detection ..
  65. ncbi Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients
    Helle Brit Fiebrich
    Department of Medical Oncology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands
    Eur J Cancer 45:2312-5. 2009
    ..Distinguishing a SPM from carcinoid lesions is therefore important. Differentiation can be achieved using the difference in uptake between different positron emission tomography (PET) tracers...
  66. ncbi Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis
    Giorgio Treglia
    Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8, Rome 00168, Italy
    Pediatr Radiol 42:1372-9. 2012
    We performed a meta-analysis on published data on the diagnostic performance of fluorine-18 dihydroxyphenylalanine ((18)F-DOPA) positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI).
  67. ncbi 18F-DOPA PET/CT but not 68Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome
    Camilla Schalin-Jantti
    Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, PO Box 340, FI 00290 Helsinki, Finland
    Clin Nucl Med 37:904-5. 2012
    ..Ga-DOTA-TOC PET/CT, which is recommended as the first-line PET imaging, was performed, but it was not diagnostic. Imaging with F-DOPA PET/CT revealed the underlying cause...
  68. ncbi Catabolism of L-phenylalanine and L-tyrosine by Rhodobacter sphaeroides OU5 occurs through 3,4-dihydroxyphenylalanine
    N K Ranjith
    Department of Plant Sciences, School of Life Sciences, University of Hyderabad, P O Central University, Hyderabad 500 046, India
    Res Microbiol 158:506-11. 2007
    ..The metabolites of l-phenylalanine catabolism, i.e. 4-hydroxy phenylalanine (l-tyrosine), 3,4-dihydroxyphenylalanine (DOPA), 3,4-dihydroxyphenyl-pyruvic acid (DOPP), 3,4-dihydroxyphenyllactic acid (DOPLA), 3,4-..
  69. ncbi Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?
    Michael Hentschel
    Departments of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany
    Clin Nucl Med 37:e24-9. 2012
    To define the appropriate scan time for fluorine-18-labeled dihydroxyphenylalanine (F-18 DOPA) PET in oncological imaging of pheochromocytomas and paragangliomas.
  70. ncbi Chemoenzymatic synthesis of peptidyl 3,4-dihydroxyphenylalanine for structure-activity relationships in marine invertebrate polypeptides
    Steven W Taylor
    Center for Marine Biotechnology and Biomedicine, University of California, San Diego, La Jolla, California, 92093 0204, USA
    Anal Biochem 302:70-4. 2002
    An improved method for hydroxylating tyrosine-containing sequences in polypeptides to peptidyl 3,4-dihydroxyphenylalanine (DOPA) using mushroom tyrosinase at relatively high enzyme-to-substrate ratios is described...
  71. ncbi PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting
    Valerie N Yakemchuk
    Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Nucl Med Commun 33:322-30. 2012
    ..This study assessed the diagnostic accuracy of 6-[¹⁸F]fluoro-3,4-dihydroxyphenylalanine (¹⁸F-FDOPA) PET/CT in neuroendocrine tumors.
  72. ncbi Stability of collagen in the presence of 3,4-dihydroxyphenylalanine (DOPA)
    R Usha
    Biophysics Laboratory, Central Leather Research Institute, Chennai, India
    J Photochem Photobiol B 97:34-9. 2009
    ..L-DOPA (3,4-dihydroxyphenylalanine), a neurotransmitter, is a naturally present compound in the living system and is the target in ..
  73. pmc Strong reversible Fe3+-mediated bridging between dopa-containing protein films in water
    Hongbo Zeng
    Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 2V4 Canada
    Proc Natl Acad Sci U S A 107:12850-3. 2010
    ..Mfp-1, containing 13 mol % of dopa (3, 4-dihydroxyphenylalanine) side-chains, is highly positively charged polyelectrolyte (pI approximately 10) and didn't show any ..
  74. ncbi Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys
    Albert Hsu
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    J Pharmacol Exp Ther 311:770-7. 2004
    Although l-3,4-dihydroxyphenylalanine (L-dopa) is one of the most effective therapies for Parkinson's disease, continued treatment may result in excessive involuntary movements known as L-dopa-induced dyskinesias (LIDs)...
  75. ncbi Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques
    N P Visanji
    Division of Brain Imaging and Behavior, Toronto Western Research Institute, 399 Bathurst St, Toronto, ON, Canada
    J Pharmacol Exp Ther 328:276-83. 2009
    The mechanisms underlying actions of dihydroxyphenylalanine (L-DOPA) in Parkinson's disease remain to be fully elucidated. Noradrenaline formed from L-DOPA may stimulate alpha(1)-adrenoceptors...
  76. pmc Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
    P K Morrish
    MRC Cyclotron Unit Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 64:314-9. 1998
    ....
  77. ncbi Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    J Pediatr 150:140-5. 2007
    To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism.
  78. pmc Single-molecule mechanics of mussel adhesion
    Haeshin Lee
    Department of Biomedical Engineering and Materials Science and Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA
    Proc Natl Acad Sci U S A 103:12999-3003. 2006
    ....
  79. ncbi Synthesis of dopamine from L-3,4-dihydroxyphenylalanine by human amniotic epithelial cells
    M A Elwan
    Department of Inherited Metabolic Diseases, National Institute of Neuroscience, NCNP, Kodaira, Tokyo, Japan
    Eur J Pharmacol 354:R1-2. 1998
    In this study, the ability of human amniotic epithelial cells to synthesize dopamine from L-3,4-dihydroxyphenylalanine (L-DOPA) was examined...
  80. ncbi RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease
    Stephen J Gold
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    J Neurosci 27:14338-48. 2007
    ..However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa...
  81. ncbi The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma
    I S Mackenzie
    Clinical Pharmacology Unit, Department of Nuclear Medicine, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    Eur J Endocrinol 157:533-7. 2007
    ..of phaeochromocytoma, but who had negative 123I-MIBG scans, and illustrate the usefulness of 18-fluoro-dihydroxyphenylalanine PET scanning in their assessment...
  82. pmc Adhesion mechanisms of the mussel foot proteins mfp-1 and mfp-3
    Qi Lin
    Department of Chemical Engineering, Graduate Program in Biomolecular Science and Engineering, University of California Santa Barbara, Santa Barbara, CA 93106, USA
    Proc Natl Acad Sci U S A 104:3782-6. 2007
    ..g., their inability to be peeled off) rather than a high intrinsic surface or adhesion energy, W...
  83. ncbi Linking adhesive and structural proteins in the attachment plaque of Mytilus californianus
    Hua Zhao
    Department of Molecular, Cellular and Developmental Biology, Marine Science Institute, University of California, Santa Barbara, California 93106, USA
    J Biol Chem 281:26150-8. 2006
    ..5-S-Cysteinyldopa was detected at nearly 1 mol %. The results suggest that mcfp-6 may provide a cohesive link between the surface-coupling Dopa-rich proteins and the bulk of the plaque proteins...
  84. ncbi Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study
    Klaas P Koopmans
    Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen, Netherlands
    Lancet Oncol 7:728-34. 2006
    ..We aimed to test the diagnostic sensitivity of 6-[fluoride-18]fluoro-levodopa ((18)F-DOPA PET), compared with conventional imaging methods, in patients with carcinoid tumours...
  85. ncbi Towards the development of selective amine oxidase inhibitors. Mechanism-based inhibition of six copper containing amine oxidases
    Eric M Shepard
    Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59717, USA
    Eur J Biochem 269:3645-58. 2002
    ..Collectively, these results suggest that the development of highly selective amine oxidase inhibitors is feasible...
  86. ncbi 2,4,5-Trihydroxyphenylalanine quinone biogenesis in the copper amine oxidase from Hansenula polymorpha with the alternate metal nickel
    Nicole M Samuels
    Department of Chemistry, University of California, Berkeley, California 94720, USA
    Biochemistry 44:14308-17. 2005
    ..Detailed kinetic analysis of the mechanism of TPQ biogenesis for the Ni(II)-substituted enzyme has led to the proposal of a direct electron transfer from the metal-coordinated tyrosinate to dioxygen as the dominant rate-limiting step...
  87. ncbi The crystal structure of Pichia pastoris lysyl oxidase
    Anthony P Duff
    School of Molecular and Microbial Biosciences, University of Sydney, Sydney, NSW, Australia
    Biochemistry 42:15148-57. 2003
    ..The structural elements that are responsible for the accessibility of the active site are identified and discussed...
  88. ncbi Catalytic mechanism of the topa quinone containing copper amine oxidases
    Minae Mure
    Department of Chemistry, University of California, Berkeley, California 94720, USA
    Biochemistry 41:9269-78. 2002
  89. ncbi A theoretical study of the dioxygen activation by glucose oxidase and copper amine oxidase
    Rajeev Prabhakar
    Department of Physics, Stockholm Centre for Physics, Astronomy and Biotechnology SCFAB, Stockholm University, S 106 91 Stockholm, Sweden
    Biochim Biophys Acta 1647:173-8. 2003
    ..For CAO, a mechanism for the O[bond]O cleavage step in the biogenesis of TPQ is also suggested...
  90. ncbi Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene
    Stefania Di Candia
    Department of Pediatrics, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy
    Eur J Endocrinol 160:1019-23. 2009
    ..application of positron emission tomography (PET)/computed tomography (CT) scanning with 18-fluoro-l-3,4 dihydroxyphenylalanine improved the ability to distinguish the two histopathologic forms of HI (focal and diffuse), whose ..
  91. ncbi Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats
    Christophe Jollivet
    INSERM U 646, Batiment IBT, 10 rue Andre Boquel, 49100 Angers, France
    Neurosci Lett 362:79-82. 2004
    ..Moreover, we have shown that L-DOPA treatment for 2 weeks or nerve growth factor treatment for 8 weeks are able to dramatically augment their number...
  92. ncbi Human kidney diamine oxidase: heterologous expression, purification, and characterization
    Bradley O Elmore
    Department of Chemistry and Biochemistry, Montana State University, Bozeman 59717, USA
    J Biol Inorg Chem 7:565-79. 2002
    ..0 and 8.2. Tissue-specific expression of the human diamine oxidase gene was investigated using an mRNA array. The relevance of this work to earlier work and the suggested physiological roles of the human enzyme are discussed...
  93. ncbi Styelin D, an extensively modified antimicrobial peptide from ascidian hemocytes
    S W Taylor
    Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92093 0204, USA
    J Biol Chem 275:38417-26. 2000
    ..acids, dihydroxyarginine and dihydroxylysine, and two distinctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine. In addition, the peptide exhibited microheterogeneity because of differential mono- and dihydroxylation ..
  94. ncbi Crystal structure of a quinoenzyme: copper amine oxidase of Escherichia coli at 2 A resolution
    M R Parsons
    Department of Biochemistry and Molecular Biology, University of Leeds, UK
    Structure 3:1171-84. 1995
    ....
  95. ncbi Effect of metal substitution in copper amine oxidase from lentil seedlings
    A Padiglia
    Department of Sciences Applied to Biosystems University of Cagliari, I 09042 Cagliari, Italy
    J Biol Inorg Chem 4:608-13. 1999
    ..The results obtained show that although Co-substituted amine oxidase is catalytically competent, copper is essential for the catalytic mechanism...
  96. pmc Roles of tyrosine-rich precursor glycoproteins and dityrosine- and 3,4-dihydroxyphenylalanine-mediated protein cross-linking in development of the oocyst wall in the coccidian parasite Eimeria maxima
    Sabina I Belli
    Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Gore Hill, New South Wales, Australia
    Eukaryot Cell 2:456-64. 2003
    ..The identification of high concentrations of dityrosine and 3,4-dihydroxyphenylalanine (DOPA) in oocyst extracts by high-pressure liquid chromatography, together with the detection of a UV ..
  97. ncbi X-ray snapshots of quinone cofactor biogenesis in bacterial copper amine oxidase
    Misa Kim
    School of Science and Technology, Kwansei Gakuin University, Sanda, Hyogo 669 1337, Japan
    Nat Struct Biol 9:591-6. 2002
    ..formation of freeze-trapped intermediates; structural analyses indicate that these intermediates contain dihydroxyphenylalanine quinone and trihydroxyphenylalanine...
  98. ncbi Properties of copper-free pig kidney amine oxidase: role of topa quinone
    Anna Mura
    Department of Applied Sciences in Biosystems, University of Cagliari, Cagliari, Italy
    FEBS Lett 580:4317-24. 2006
    ..However, Co-reconstituted enzyme only shows a very low activity. These results demonstrate that copper is essential for the catalytic mechanism because it maintains the correct active site geometry...
  99. ncbi Selective fluorogenic derivatization of 3-nitrotyrosine and 3,4-dihydroxyphenylalanine in peptides: a method designed for quantitative proteomic analysis
    Victor S Sharov
    Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA
    Methods Enzymol 441:19-32. 2008
    ..a method for the selective derivatization of 3-nitrotyrosine (after reduction to 3-amino-tyrosine) and 3,4-dihydroxyphenylalanine with benzylamine derivatives to yield 6-amino- and 6-benzylamine-substituted benzoxazoles, which display ..
  100. ncbi Copper amine oxidase: cunning cofactor and controversial copper
    H C Dawkes
    Astbury Centre for Structural Molecular Biology, School of Biochemistry and Molecular Biology, University of Leeds, LS29JT, Leeds, UK
    Curr Opin Struct Biol 11:666-73. 2001
    ..Although dioxygen has been directly observed bound to the copper at a late stage in the reaction cycle, whether copper is the initial binding site remains controversial...
  101. ncbi Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma
    E Eldrup
    Department of Internal Medicine E Herlev Hospital, University of Copenhagen, Denmark
    Scand J Clin Lab Invest 61:479-90. 2001
    ..Plasma (p-) levels of 3,4-dihydroxyphenylalanine (DOPA) are increased in most NB, probably reflecting decreased DOPA decarboxylase activity...

Research Grants54

  1. Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and Disease
    John J Mieyal; Fiscal Year: 2012
    ..L-dihydroxyphenylalanine (levodopa, L-DOPA) is the drug of choice for treatment of the symptoms of this disease, serving to ..
  2. BIOGENESIS OF MELANOSOMES
    Seth J Orlow; Fiscal Year: 2013
    ..that catalyzes the first, rate-limiting step in melanin synthesis, namely conversion of L-tyrosine to dihydroxyphenylalanine. Tyrosinase is a determinant of skin pigmentation and risk of cutaneous cancers...
  3. Novel Polymer Coatings to Prevent Biofilms on Urinary Stents and Catheters
    JEFFREY LAWRENCE DALSIN; Fiscal Year: 2011
    ..In brief, antifouling polymers have been coupled to the amino acid L-3,4-dihydroxyphenylalanine (DOPA), a key component of so-called mussel adhesive proteins (MAPs)...
  4. Biologically Inspired Polymer Adhesives
    Phillip B Messersmith; Fiscal Year: 2013
    ..micro- and macro-scale adhesion experiments to gain a detailed understanding of the adhesive role of L-3,4-dihydroxyphenylalanine (DOPA) and other key residues in mussel adhesion, and to use this information to motivate the design of ..
  5. A novel desensitizing paste containing enamel-like crystals
    Scott I Merz; Fiscal Year: 2012
    ..are the same as those found in dental enamel and synthetic polymer which mimics the naked amino acid 3,4 dihydroxyphenylalanine (DOPA) found in the mussel adhesive mucus...
  6. Striatal cholinergic neurons and L-DOPA induced dyskinesia
    Un Jung Kang; Fiscal Year: 2013
    ..L-dihydroxyphenylalanine (L-DOPA) therapy alleviates the motor symptoms, however the utility of this agent for chronic treatment is ..
  7. PSYCHOMOTOR STIMULANTS AND ADRENERGIC NERVE FUNCTION
    Charles Smith; Fiscal Year: 1991
    ..the release of 3H-norepinephrine after incubating the tissues with 3H-norepinephrine or its precursor, 3H- dihydroxyphenylalanine, b) the efflux of endogenous neurotransmitter by a combination of high pressure liquid chromatography and ..
  8. NOVEL SIGMA RECEPTOR LIGANDS IN NEURODEGENERATION
    Raymond Booth; Fiscal Year: 2000
    ..In vivo sigma3 receptor- mediated effects on synthesis and release of 3,4-dihydroxyphenylalanine (DOPA) and catecholamines will be measured in specific brain regions by HPLC-EC, after administering PATs ..
  9. Chemical Biology Approaches to Combat Parkinson's Disease and Dyskinesia
    Dewey G McCafferty; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but long- term L-DOPA administration is marred by the emergence of motor complications, namely, ..
  10. HORMONAL CONTROL OF HYPOTHALAMIC DOPAMINE SECRETION
    John Porter; Fiscal Year: 1992
    ..The in situ enzymic activity of TH in hypothalamic dopaminergic neurons will be assayed using an L-dihydroxyphenylalanine (DOPA) accumulation procedure...
  11. NEUROENDOCRINE EFFECTS OF PERINATAL OPIATE EXPOSURE
    JAMES VOOGT; Fiscal Year: 1992
    ..Dopamine and serotonin synthesis in the nerve terminals will be measured by in vitro accumulation of L-dihydroxyphenylalanine in the stalk-median eminence and 5-hydroxytryptophan in the medial basal hypothalamus after incubation ..
  12. ORGAN SPECIFIC DRUGS: CARDIOVASCULAR AND RENAL EFFECTS
    Marian Orlowski; Fiscal Year: 1980
    ..e., L-yield-glutamyl-L-3,4-dihydroxyphenylalanine)...
  13. Dopamine regulation in parkinsonian rat by gene therapy
    Un Kang; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): L-3,4-dihydroxyphenylalanine (L-DOPA) is the mainstay of therapy for Parkinson's disease (PD)...
  14. Epidemilogy of Parkinsonism in Welders
    Brad A Racette; Fiscal Year: 2011
    ..The cohort assembled will provide unique opportunities for future research projects into gene-environment interactions and exposure related neuroimaging changes. ..
  15. GENETICS OF PARKINSON DISEASE IN THE AMISH
    Brad Racette; Fiscal Year: 2006
    ..abstract_text> ..
  16. MELANOGENESIS IN CRYPTOCOCCUS NEOFORMANS
    JOSHUA NOSANCHUK; Fiscal Year: 2002
    ..To explore the structure of melanin using biochemistry, phage display peptide libraries and mAbs; and 4. To use peptides and mAbs to study C. neoformans melanogenesis in vivo and in vitro. ..
  17. PROLIFERATION & MALIGNANT TRANSFORMATION OF MELANOCYTES
    Ruth Halaban; Fiscal Year: 2004
    ..Our functional studies may provide a basis for the design of new therapeutical agents for the treatment of patients with metastatic melanomas. ..
  18. Epigenetic Chromatin Changes as Melanoma Markers
    Ruth Halaban; Fiscal Year: 2006
    ..Altogether, the results are likely to generate a novel marker(s) that can be used to assess propensity for malignant transformation, tumor progression and/or sensitivity to chemotherapeutic drugs that target chromatin conformation. ..
  19. Antibody Protection in Histoplamosis
    JOSHUA NOSANCHUK; Fiscal Year: 2009
    ..These studies are expected to lead to insights into H. capsulatum pathogenesis and initiate the development of new therapeutic and diagnostic reagents. ..
  20. 2003 Conference Pan-American Society Pigment Cell Resea
    Ruth Halaban; Fiscal Year: 2003
    ..3. To provide partial support to students and junior faculty to attend the meeting. They request funds for the 2003 meeting as well as for the 2 subsequent PASPCR annual meetings in years 2004 and 2006. ..
  21. Role of dopamine D1 receptors in morphine withdrawal
    Elena Chartoff; Fiscal Year: 2006
    ..This work may lead to new pharmacotherapies that can alleviate aversive and dysphoric states associated with opiate withdrawal and perhaps reduce relapse to drug taking. ..
  22. PF-L-DOPA: a MRI tool for developmental neurobiology
    Sherry Dingman; Fiscal Year: 2005
    ..This new MRI methods will reveal structural and functional brain alterations during development, making it possible to monitor the neurobiological impact of exposure to drugs. ..
  23. Bioadhesive Polymer Hydrogels: Basic and Applied Studies
    PHILLIP MESSERSMITH; Fiscal Year: 2005
    ..These protein 'glues' can be characterized as having a high concentration of L- 3,4-dihydroxyphenylalanine (DOPA), an amino acid that is believed to be responsible for both adhesive and crosslinking ..
  24. DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS
    Jeffrey Kordower; Fiscal Year: 2006
    ..This application will determine whether potent dopaminergic gene therapies influence dyskinesias in the best animal model of PD. ..
  25. Bioinspired Synthesis of In-Situ Gelling Biomaterials
    PHILLIP MESSERSMITH; Fiscal Year: 2007
    ..abstract_text> ..
  26. Consequences of repeated kappa receptor activation on brain stimulation reward
    Elena Chartoff; Fiscal Year: 2006
    ..abstract_text> ..
  27. TH and GTPCHI gene therapy for Parkinson's disease
    Jeffrey H Kordower; Fiscal Year: 2010
    ..These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials. ..
  28. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  29. MASS SPECTROMETER
    Wolfgang Fischer; Fiscal Year: 2001
    ..A significant institutional commitment will ensure that this instrument is operated and maintained by trained personnel. All measurements will be made under the supervision of A. Craig. ..
  30. THE BIOLOGY OF PROGRESSIVE NEPHRON DESTRUCTION
    Raymond Harris; Fiscal Year: 2007
    ..abstract_text> ..
  31. NPY Induced Regulation of Sympathetic Neurotransmission
    THOMAS WESTFALL; Fiscal Year: 2006
    ..These studies will provide useful new information on the functional role and mechanism of action of NPY in the prejunctional regulation of sympathetic neurotransmission. ..
  32. Translational Studies on Smoking in Schizophrenia
    Tony George; Fiscal Year: 2006
    ..Ultimately, this K02 would support two new and integrated projects that will correlate neurocognitive, genetic and biochemical assessments with smoking cessation treatment response in schizophrenic patients. ..
  33. Optimizing Treatment for Schizophrenic Smokers
    Tony George; Fiscal Year: 2004
    ..The results of this study could provide valuable information on effective medication treatments for cigarette smoking in schizophrenic patients. ..
  34. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  35. ROBUST PROTEIN FROM MUSSEL BYSSUS
    JOHN WAITE; Fiscal Year: 2003
    ..The outcome of these should be of particular relevance to the design of scaffolding biomaterials with a wide range of mechanical properties. ..
  36. Nicotinic Receptors and Cog Function in Schizophrenia
    Tony George; Fiscal Year: 2003
    ..control smokers, and suggest novel treatment approaches for both nicotine dependence and cognitive dysfunction in schizophrenic disorders. ..
  37. AROMATIC L-AMINO ACID DECARBOXYLASE MODULATION
    NORTON NEFF; Fiscal Year: 2003
    ..This proposal has direct clinical relevance for PD, as it addresses the functionality of an enzyme absolutely required for successful L-DOPA therapy. ..
  38. PHENOLS/CATECHOLS IN OCCUPATIONAL/CONTACT VITILIGO SKIN
    Raymond Boissy; Fiscal Year: 2002
    ....
  39. ON THE ROLE OF THE HPS GENE PRODUCT IN MELANOCYTES
    Raymond Boissy; Fiscal Year: 2002
    ..These studies will contribute to our knowledge of cellular trafficking in general and the pathophysiology of HPS in specific. ..
  40. DOPAMINE AND RETINAL ADAPTATION
    Paul Witkovsky; Fiscal Year: 2001
    ....
  41. 2004 National Vitiligo Foundation Scientific Conference
    Raymond Boissy; Fiscal Year: 2004
    ..In addition, mini-symposiums will be organized for each of the sessions. ..
  42. HYDROXYNONENAL MODIFICATION OF SUPEROXIDE DISMUTASE
    Kenneth Hensley; Fiscal Year: 2002
    ..abstract_text> ..
  43. Mussel-Inspired Protective Coatings
    JOHN WAITE; Fiscal Year: 2006
    ..All films will be evaluated by macro- and nanomechanical tests, and their resistance to a diverse range of biochemical, thermal, and mechanical insults will be examined. ..
  44. Dynamically Crosslinked Hydrogels
    Russell Stewart; Fiscal Year: 2006
    ..These novel hydrogels may find wide ranging biomedical applications in drug delivery, as active surface coatings or microactuators in medical devices. ..
  45. Physiology and Anatomy of the Basal Ganglia
    Hitoshi Kita; Fiscal Year: 2006
    ..At the end of the proposed projects, we should be able to offer an anatomical and physiological basis for explaining how the synaptic inputs might control the neuronal activity of the GPe. ..
  46. 2005 Gordon Conference on Catecholamines
    David Sulzer; Fiscal Year: 2005
    ..abstract_text> ..
  47. Self-immobilizing Proteins
    Russell Stewart; Fiscal Year: 2005
    ..The widely expected future impact of protein arrays on clinical diagnosis and other areas of human health care may be realized more quickly with new and effective protein modification technology. ..
  48. Biomimetic Blades: Mincing with Less Mineral
    JOHN WAITE; Fiscal Year: 2005
    ..The chief health benefits of this research will be insights about lightweight replacement materials with superior hardness and abrasion resistance. ..
  49. Virulence Factor Trafficking in Cryptococcus
    Peter Williamson; Fiscal Year: 2005
    ..Each of the mutants identified in Specific Aims 2 and 3 will then be assessed for production of other virulence-related factors such as capsule, urease, phospholipase and virulence in a mouse model. ..
  50. Role of CRH in skin physiology and pathology
    Andrzej Slominski; Fiscal Year: 2004
    ..g., melanocytes and keratinocytes, and test the role of CRH/CRH-R1 axis in the regulation of human hair growth. ..
  51. 2008 Biointerface Science Gordon Research Conference
    PHILLIP MESSERSMITH; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  52. Research Training in Nuclear Molecular Imaging
    Alan Fischman; Fiscal Year: 2007
    ..abstract_text> ..